-Tolvaptan%20Structural%20Formula%20V1.svg)
tolvaptan
Sign in to saveAlso known as OPC-41061, Samsca®
Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca. Tolvaptan, as Jynarque, was granted approval for medical use in the United States in April 2018.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470611744
- Drug.IUPAC_name
- N-(4-{[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide
- Drug.image
- (RS)-Tolvaptan Structural Formula V1.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Tolvaptan ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Samsca, Jinarc, Jynarque, others
- Drug.MedlinePlus
- a609033
- Drug.DailyMedID
- Tolvaptan
- Drug.pregnancy_category
- UK: Contraindicated
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- C03
- Drug.ATC_suffix
- XA01
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
1,795 papersvia PubMed
~4 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Chemistry
- References
- Further reading
- External links
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 470611744 | IUPAC_name = N-(4-{[(5R)-7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl}-3-methylphenyl)-2-methylbenzamide | image = (RS)-Tolvaptan Structural Formula V1.svg | image_class = skin-invert-image | image2 = Tolvaptan ball-and-stick model.png | image_class2 = bg-transparent
| tradename = Samsca, Jinarc, Jynarque, others | Drugs.com = | MedlinePlus = a609033 | DailyMedID = Tolvaptan | pregnancy_AU = | pregnancy_category = UK: Contraindicated | routes_of_administration = By mouth | ATC_prefix = C03 | ATC_suffix = XA01 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_CA = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_status = | protein_bound = 99% | metabolism = Liver (CYP3A4-mediated) | elimination_half-life = 12 hours (terminal) | excretion = | CAS_number_Ref = | CAS_number = 150683-30-0 | PubChem = 216237 | IUPHAR_ligand = 2226 | DrugBank_Ref = | DrugBank = DB06212 | ChemSpiderID_Ref = | ChemSpiderID = 187438 | UNII_Ref = | UNII = 21G72T1950 | ChEMBL_Ref = | ChEMBL = 344159 | ChEBI = 32246 | KEGG = D01213
Excerpted from Wikipedia’s “tolvaptan” article, available under the CC BY-SA 4.0 licence.